ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Cytomeglovirus"

  • 2015 American Transplant Congress

    Incidence of CMV Viremia in Obese and Morbidly Obese Kidney Transplants Under a Low Dose Valganciclovir Prophylaxis Protocol

    J. Thielke,1 P. West-Thielke,2 E. Benedetti.2

    1Pharmacy Practice, Univ of IL-Chicago, Chicago, IL; 2Surgery, Univ of IL-Chicago, Chicago, IL.

    Background: The rate of Cytomegalovirus infections in kidney transplant recipients drastically diminished with the advent of oral ganciclovir and subsequently valganciclovir. However it continues to…
  • 2015 American Transplant Congress

    Favorable Long-Term Outcome of Late-Onset CMV Disease in D+R- Kidney Transplant Recipients Treated With Universal Prophylaxis

    H. Kaminski,1 L. Couzi,1,2 I. Garrigue,3,4 J. Déchanet-Merville,2 P. Merville.1,2

    1Nephrologie-Transplantation-Dialyse, CHU Bordeaux, Bordeaux, France; 2Unité Mixte de Recherche 5164, Centre National de la Recherche Scientifique, Bordeaux, France; 3Laboratoire de Virologie, CHU Bordeaux, Bordeaux, France; 4Unité Mixte de Recherche 5234, Centre National de la Recherche Scientifique, Bordeaux, France.

    Based on last international guidelines, both universal prophylaxis and preemptive strategies are viable approaches for the prevention of cytomegalovirus (CMV) disease after organ transplantation. Universal…
  • 2015 American Transplant Congress

    Diabetic Kidney Transplant Recipients: Impaired Infection Control and Alloreactivity

    T. Schachtner,1,2 M. Stein,2 P. Reinke.1,2

    1Nephrology and Internal Intensive Care, Charité Campus Virchow Clinic, Berlin, Germany; 2Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany.

    New onset diabetes after transplant (NODAT) has been associated with an increased risk of infection and sepsis. Previous studies, however, failed to identify differences in…
  • 2015 American Transplant Congress

    African American Race Is an Independent Risk Factor for Cytomegalovirus Infection in Renal Transplant Recipients on Low-Dose Valganciclovir Prophylaxis

    S. Patel, S. Kuten, J. Loucks-DeVos, R. Knight, A. Gaber.

    Houston Methodist Hospital, Houston, TX.

    Safe and effective use of low-dose (450 mg/day) valganciclovir (VGC) for cytomegalovirus (CMV) prophylaxis in renal transplant recipients (RTRs) has been reported. However, it is…
  • 2015 American Transplant Congress

    Recipient Immunity to Murine Cytomegalovirus Influences Natural Killer Cell Responses in Infected Renal Allografts

    M. Shimamura,1 M. Li,1 B. Chen,2 J. George.2

    1Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL; 2Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham.

    BACKGROUND: Human cytomegalovirus (CMV) is associated epidemiologically with renal allograft loss, but the impact of recipient CMV immunity upon graft survival is unclear. Natural killer…
  • 2015 American Transplant Congress

    Recurrent Cytomegalovirus Infection After Solid Organ Transplant

    Y. Natori, A. Humar, S. Husain, C. Rotstein, D. Kumar.

    University Health Network, Toronto, Canada.

    Background:Cytomegalovirus is a common opportunistic infection after transplant. Relapse may occur after treatment of the initial episode of viremia or disease and secondary prophylaxis is…
  • 2015 American Transplant Congress

    Epigenetic Reprogramming of Murine Cytomegalovirus Immediate Early Genes Induced By Renal Transplantation

    M. Hummel,1 X.-F. Liu,1 C. Jie,1 Z. Zhang,1 S. Yan,1 J.-J. Wang,1 S. Kurian,2 D. Salomon,2 M. Abecassis.1

    1Comprehensive Transplant Center, Northwestern University, Chicago, IL; 2Dept of Molecular and Experimental Medicine, The Scripps Research Institute, LaJolla, CA.

    Background: Reactivation of latent CMV is a significant infectious complication in solid organ transplant recipients. MCMV is a valuable model for studying molecular mechanisms controlling…
  • 2015 American Transplant Congress

    Safety and Outcome of Ganciclovir-Resistant CMV Treated With Foscarnet: A Single Center Retrospective Study

    B. Pierce,4 C. Richardson,4 K. Cunningham,4 C. D'Agostino,4 C. Tseng,4 J. Brown,4 C. O'Brien,4 B. Ho,1,3,5 M. Ison.1,2,3

    1Department of Medicine, Northwestern Medicine, Chicago, IL; 2Division of Infectious Diseases, Northwestern Medicine, Chicago, IL; 3Division of Organ Transplantation, Northwestern Medicine, Chicago, IL; 4Pharmacy, Northwestern Medicine, Chicago, IL; 5Transplant Nephrology, Northwestern Medicine, Chicago, IL.

    Background: Infection with cytomegalovirus (CMV) is an important cause of morbidity and mortality following solid organ transplantation (SOT). Resistance can rarely develop via mutations in…
  • 2015 American Transplant Congress

    A Prospective Pilot Study Evaluating the Safety and Efficacy of Everolimus for the Prevention of CMV and BK Viral Infection (BKV) in Broadly Sensitized Kidney Transplant Recipients Following Desensitization With IVIG and Rituximab: Interim Analysis

    J. Kahwaji,1 S. Louie,1 A. Vo,1 J. Choi,1 M. Toyoda,2 S. Ge,2 P. Wongsaroj,1 A. Peng,1 R. Villicana,1 S. Jordan.1

    1Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; 2Transplant Immunology Lab, Cedars-Sinai Medical Center, Los Angeles, CA.

    Introduction: Everolimus, a second generation mTOR inhibitor, may prevent CMV and BKV infection after kidney transplantation. Broadly sensitized patients are at greater risk of viral…
  • 2015 American Transplant Congress

    Implementation of Evidence-Based Guidelines for Cytomegalovirus Prevention in Pediatric Solid Organ Transplantation

    L. Danziger-Isakov, T. Hemmelgarn, R. Kohli, D. Lazear, M. Lake, J. Goebel, C. Castleberry, J. Courter, S. Kacoshis, M. Schecter, D. Witte, E. Clark, J. Bucuvalas.

    Cincinnati Children's, Cincinnati.

    Optimal strategies to prevent cytomegalovirus (CMV) disease after pediatric solid organ transplantation (SOT) in a cost effective manner are uncertain. We evaluated the frequency of…
  • « Previous Page
  • 1
  • …
  • 30
  • 31
  • 32
  • 33
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences